Periodontal DiseaseGLP1-PERIONCT07770906
Effect of GLP-1 Receptor Agonists on Periodontal Health and Response to Nonsurgical Periodontal Therapy
A study testing non-surgical periodontal therapy in people with Periodontal Disease and Obesity & Overweight, run by Cukurova University.
Trial summary
This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Periodontal Disease, Obesity & Overweight
- What is being tested?
- non-surgical periodontal therapy
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 1 Dec 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age between 18 and 65 years
- Body mass index (BMI) ≥25 kg/m²
- Presence of at least 20 functional teeth
- Diagnosis of periodontitis
- For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months
Who cannot join
- Age between 18 and 65 years
- Body mass index (BMI) ≥25 kg/m²
- Presence of at least 20 functional teeth
- Diagnosis of periodontitis
- For the GLP-1 receptor agonist group: regular use of a GLP-1 receptor agonist for at least 3 months
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Glucagon-Like Peptide-1 Receptor Agonist Use on Periodontal Health and Response to Non-Surgical Periodontal Therapy
This study aims to evaluate the effects of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on periodontal health and the response to non-surgical periodontal therapy in individuals with obesity and periodontitis.
Participants with obesity and periodontitis will be divided into two groups: those who have been using a GLP-1 RA for at least 3 months and those who are not using any medication for obesity. All participants will receive the same non-surgical periodontal treatment, including oral hygiene instruction, scaling, and root planing.
Periodontal clinical measurements and gingival crevicular fluid samples will be collected before treatment and at 3 and 6 months after treatment. The study will compare changes in periodontal health and inflammatory markers between the two groups to determine whether GLP-1 RA use is associated with periodontal health and the response to non-surgical periodontal therapy.
Read the detailed description
This prospective, controlled clinical study aims to compare periodontal clinical parameters and gingival crevicular fluid inflammatory markers between individuals with obesity and periodontitis who use GLP-1 RAs and those who do not use pharmacological treatment for obesity. The study will also evaluate and compare the clinical response to non-surgical periodontal therapy between the two groups.
A total of 40 participants with obesity and periodontitis will be included and allocated to two groups. The GLP-1 RA group will consist of 20 participants who have been regularly using a GLP-1 RA (semaglutide, liraglutide, or dulaglutide) for at least 3 months because of obesity. The control group will consist of 20 participants with obesity and periodontitis who are not using any medication for obesity.
All participants will receive the same non-surgical periodontal treatment protocol. Following the baseline periodontal examination, participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be completed in two sessions under local anesthesia and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used. Participants in the GLP-1 RA group will continue their existing systemic GLP-1 RA treatment without modification.
Periodontal clinical assessments will include probing depth, clinical attachment level, bleeding on probing, plaque index, and gingival index. Gingival crevicular fluid samples will be collected using sterile PerioPaper® strips and stored at -80°C until analysis. Body mass index, HbA1c, and fasting blood glucose will also be evaluated using the measurements and laboratory results specified in the study protocol.
Clinical periodontal measurements and gingival crevicular fluid sampling will be performed at baseline and repeated at 3 and 6 months following non-surgical periodontal therapy. During follow-up visits, oral hygiene instructions will be reinforced, and professional supragingival cleaning will be performed when supragingival calculus accumulation is detected.
Changes in periodontal clinical parameters and gingival crevicular fluid inflammatory markers will be compared between the GLP-1 RA and control groups. The study is designed to determine whether GLP-1 RA use is associated with differences in periodontal inflammatory status and clinical response to non-surgical periodontal therapy in individuals with obesity and periodontitis.
- Conditions
- Periodontal Disease, Obesity & Overweight
- Being tested
- non-surgical periodontal therapy
- Keywords
- PERIODONTAL DISEASE, OBESİTY
- Medical subject headings
- Periodontal Diseases, Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
non-surgical periodontal therapyProcedure or surgery
All participants will receive oral hygiene instructions, including instruction in the modified Bass toothbrushing technique. Non-surgical periodontal therapy will be performed under local anesthesia in two sessions and will include full-mouth subgingival instrumentation and scaling and root planing using ultrasonic instruments and Gracey curettes. No adjunctive antimicrobial agents will be used.
| Study group | Role | What they receive |
|---|---|---|
| Title: GLP-1 Receptor Agonist Group | Active comparator | Not described Receives: Procedure: non-surgical periodontal therapy |
| Control Group | Placebo comparator | Not described Receives: Procedure: non-surgical periodontal therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Probing Depth
Measured: Baseline, 3 months- 6 months
Secondary outcomes (1)
Gingival Index
Measured: Baseline, 3months- 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 May 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Participants with obesity and periodontitis will be included in two parallel groups according to their existing GLP-1 receptor agonist use. One group will consist of participants who have been using a GLP-1 receptor agonist for at least 3 months, while the control group will consist of participants who are not using any medication for obesity. Both groups will receive the same non-surgical periodontal therapy and will be followed for 6 months.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cukurova University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, BAHAR ALKAYA, Cukurova University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07770906
- Sponsor's protocol ID
- TS 168- KARAR 77
- Acronym
- GLP1-PERIO
- Status last verified
- Aug 2026
- First submitted
- 13 Aug 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided